In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/ VGII by CLSI and flow cytometry

dc.creatorMorales, Bernardina Penarrieta
dc.creatorTrilles, Luciana
dc.creatorBertho, Álvaro Luiz
dc.creatorNeves Junior, Ivan
dc.creatorOliveira, Raquel de Vasconcellos Carvalhaes de
dc.creatorWanke, Bodo
dc.creatorLazéra, Márcia dos Santos
dc.date2016-04-07T13:49:03Z
dc.date2016-04-07T13:49:03Z
dc.date2015
dc.date.accessioned2023-09-26T22:21:39Z
dc.date.available2023-09-26T22:21:39Z
dc.identifierMORALES, Bernardina Penarrieta; et al. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/ VGII by CLSI and flow cytometry. Mycoses, v.58, p.273-279, 2015.
dc.identifier0933-7407
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/13637
dc.identifier10.1111/myc.12310
dc.identifier1439-0507
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8878303
dc.descriptionCryptococcus neoformans var. grubii AFLP1/VNI is the main causative agent of cryptococcosis associated with AIDS in the world. Cryptococcus gattii AFLP6/VGII causes mainly endemic primary infection in immunocompetent hosts. To determine the minimum inhibitory concentrations (MICs) of C. neoformans var. grubii AFLP1/VNI and C. gattii AFLP6/VGII against amphotericin B (AMB) in a short period of time, flow cytometry (FCM) with FUN-1 fluorochrome was used to compare with broth microdilution method (CLSI M27-A3). The minimum incubation period was evaluated by minimum fungicidal concentration procedure. Seventeen clinical isolates of C. neoformans var. grubii AFLP1/VNI and 18 of C. gattii AFLP6/VGII were analysed. The time for the determination of MICs by FCM was 2 h against 72 h by CLSI M27- A3 and the comparison of MIC showed a positive significant correlation (P = 0.048). It is important to highlight the role of the FCM as an alternative method to determine the MICs for AMB in within a day, with positive cost-benefit.
dc.formatapplication/pdf
dc.languageeng
dc.publisherWiley
dc.rightsrestricted access
dc.subjectCryptococcus neoformans
dc.subjectCryptococcus gattii
dc.subjectamphotericin B
dc.subjectCLSI M27-A3
dc.subjectFlow cytometry
dc.subjectCryptococcus neoformans
dc.subjectCitometria de Fluxo
dc.subjectCryptococcus gattii
dc.subjectAnfotericina B
dc.titleIn vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/ VGII by CLSI and flow cytometry
dc.typeArticle


Este ítem pertenece a la siguiente institución